Antifactor Xa Activity for the Management of Anticoagulation during Cardiac Surgery
31 July 2015
28 October 2015
12 January 2016 (online)
Background In patients with autoimmune diseases associated with antiphospholipid antibodies, precise management of anticoagulation during extracorporeal circulation (ECC) is complicated. It was the aim of the present study to determine whether antifactor Xa (aXa) activity is useful in guiding heparin therapy during ECC.
Methods In 15 patients undergoing cardiac surgery, anticoagulation with unfractionated heparin (UFH) and its reversal with protamine were guided using activated clotting time (ACT) (>400 second during ECC; ≤100 second for UFH reversal). For each ACT, the corresponding aXa activity levels were measured.
Results A total of 144 blood samples were obtained. ACT and aXa activity were significantly correlated (r = 0.771, p< 0.0001, Spearman rank-order correlation). Using receiver operating characteristic curve (ROC) analyses, the cutoffvalues for aXa activity were 1.14 IU/mL (area under the ROC curve [AUC]: 0.89; inaccuracy rate: 9.4%) to predict ACT > 400 seconds and 0.55 IU/mL (AUC: 0.85; inaccuracy rate: 13.3%) for ACT ≤ 100 seconds.
Conclusion AXa activity is strongly correlated with ACT, and therefore may be feasible for managing anticoagulation with UFH during ECC.
Keywordsactivated clotting time - antifactor Xa - unfractionated heparin - cardiac surgery - extracorporeal circulation
* Both the Authors Contributed Equally to this Work.
- 1 Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 2014; 48–49: 20-25
- 2 Shapiro SS, Thiagarajan P. Lupus anticoagulants. ProgHemostThromb 1982; 6: 263-285
- 3 Djokovic A, Stojanovich L, Kontic M, Stanisavljevic N, Radovanovic S, Marisavljevic D. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J 2014; 16 (3) 162-167
- 4 Zuily S, Huttin O, Mohamed S, Marie PY, Selton-Suty C, Wahl D. Valvular heart disease in antiphospholipid syndrome. CurrRheumatol Rep 2013; 15 (4) 320
- 5 Erdozain JG, Ruiz-Irastorza G, Segura MI , et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken) 2012; 64 (8) 1256-1260
- 6 Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J ThoracCardiovascSurg 2004; 127 (2) 414-420
- 7 Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J CardiothoracSurg 2008; 33 (2) 168-181
- 8 Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. PediatrCrit Care Med 2013; 14 (2) e77-e84
- 9 Palmer K, Ridgway T, Al-Rawi O, Poullis M. Heparin therapy during extracorporeal circulation: deriving an optimal activated clotting time during cardiopulmonary bypass for isolated coronary artery bypass grafting. J Extra CorporTechnol 2012; 44 (3) 145-150
- 10 Mehta TP, Smythe MA, Mattson JC. Strategies for managing heparin therapy in patients with antiphospholipid antibody syndrome. Pharmacotherapy 2011; 31 (12) 1221-1231
- 11 East CJ, Clements F, Mathew J, Slaughter TF. Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. AnesthAnalg 2000; 90 (5) 1098-1101
- 12 Dornan RI. Acute postoperative biventricular failure associated with antiphospholipid antibody syndrome. Br J Anaesth 2004; 92 (5) 748-754
- 13 Fitch JC, Geary KL, Mirto GP, Byrne DW, Hines RL. Heparin management test versus activated coagulation time during cardiovascular surgery: correlation with anti-Xa activity. J CardiothoracVascAnesth 1999; 13 (1) 53-57
- 14 Hellstern P, Bach J, Simon M, Saggau W. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi. J Extra CorporTechnol 2007; 39 (2) 81-86
- 15 Koster A, Despotis G, Gruendel M , et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. AnesthAnalg 2002; 95 (1) 26-30
- 16 Pappalardo F, Franco A, Crescenzi G, De Simone F, Torracca L, Zangrillo A. Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration. Perfusion 2006; 21 (5) 285-290
- 17 Bull BS, Hay KL, Herrmann PC. Postoperative bypass bleeding: a bypass-associated dilutional (BAD) coagulopathy?. Blood Cells Mol Dis 2009; 43 (3) 256-259
- 18 Machin D, Devine P. The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement. J Extra CorporTechnol 2005; 37 (3) 265-271
- 19 De Waele JJ, Van Cauwenberghe S, Hoste E, Benoit D, Colardyn F. The use of the activated clotting time for monitoring heparin therapy in critically ill patients. Intensive Care Med 2003; 29 (2) 325-328
- 20 Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. AnesthAnalg 1997; 85 (3) 498-506
- 21 Koerber JM, Smythe MA, Begle RL, Mattson JC, Kershaw BP, Westley SJ. Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotherapy 1999; 19 (8) 922-931
- 22 Haselbach S, Maurer J, Vogel V , et al. A novel method for the direct determination of heparin concentration during cardiopulmonary bypass surgery. ClinChem Lab Med 2013; 51 (10) 2037-2043
- 23 Koniari I, Siminelakis SN, Baikoussis NG, Papadopoulos G, Goudevenos J, Apostolakis E. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J CardiothoracSurg 2010; 5: 101
- 24 Cho H, Jeon Y, Hong DM, Kim HJ, Min JJ. Anesthetic management of antiphospholipid syndrome patients who underwent cardiac surgery: three cases report. Korean J Anesthesiol 2014; 66 (2) 164-168
- 25 Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3, Suppl): 188S-203S
- 26 Olson JD, Arkin CF, Brandt JT , et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122 (9) 782-798
- 27 Junker R, Käse M, Schulte H, Bäumer R, Langer C, Nowak-Göttl U. Interferences in coagulation tests—evaluation of the 570-nm method on the Dade Behring BCS analyser. ClinChem Lab Med 2005; 43 (2) 244-252
- 28 Nguyen T, Musick M, Teruya J. Anticoagulation monitoring during extracorporeal membrane oxygenation: is anti-factor Xa assay (heparin level) a better test?. PediatrCrit Care Med 2014; 15 (2) 178-179
- 29 Artim-Esen B, Pericleous C, Mackie I , et al. Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Res Ther 2015; 17: 47